Design and Synthesis of Statine-Based Cell-Permeable Peptidomimetic Inhibitors of Human β-Secretase
Authors:
- 11 April 2003
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 46 (10) , 1799-1802
Abstract
We describe the development of statine-based peptidomimetic inhibitors of human β-secretase (BACE). The conversion of the peptide inhibitor 1 into cell-permeable peptidomimetic inhibitors of BACE was achieved through an iterative strategy of conceptually subdividing 1 into three regions: an N-terminal portion, a central statine-containing core, and a C-terminus. Replacement of the amino acid residues of 1 with moieties with less peptidic character was done with retention of BACE enzyme inhibitory activity. This approach led to the identification of the cell-permeable BACE inhibitor 38 that demonstrated BACE-mechanism-selective inhibition of Aβ secretion in human embryonic kidney cells.Keywords
This publication has 6 references indexed in Scilit:
- BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeuticsHuman Molecular Genetics, 2001
- Functional gamma‐secretase inhibitors reduce beta‐amyloid peptide levels in brainJournal of Neurochemistry, 2001
- Purification and cloning of amyloid precursor protein β-secretase from human brainNature, 1999
- β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACEScience, 1999
- Translating cell biology into therapeutic advances in Alzheimer's diseaseNature, 1999
- Cells with a familial Alzheimerʼs disease mutation produce authentic β-peptideNeuroReport, 1993